Lavinia Morosi

Lavinia Morosi

Auto-generated profile, based on publicly available information

Lavinia Morosi

Oncology Department, Cancer Pharmacology Laboratory, IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Via La Masa 19, 20156 Milano, Italy

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2010 in Proteomics
Verified
Journal Article
Closed access
PDF file
FRFrancesca Raimondo
Francesca Raimondo
LMLavinia Morosi
Lavinia Morosi
CCClizia Chinello
Clizia Chinello
FMFulvio Magni
Fulvio Magni
MPMarina Pitto
Marina Pitto

28 February 2013 in Molecular BioSystems
Verified
Journal Article
Closed access
PDF file
FRF. Raimondo
F. Raimondo
LML. Morosi
L. Morosi
SCS. Corbetta
S. Corbetta
CCClizia Chinello
Clizia Chinello
PBP. Brambilla
P. Brambilla
MPMarina Pitto
Marina Pitto
Renal cell carcinoma (RCC) accounts for about 3% of all human malignancies and its incidence is increasing. There are no standard biomarkers currently used in the clinical management of patients with renal cell carcinoma. A promising strategy for new biomarker detection is comparative proteomics of urinary exosomes (UE), nanovesicles released by every epithelial cell facing the urinary space, enriched in renal proteins and excluding high-abundance plasmatic proteins, such as albumin. Aim of the work is to establish the protein profile of exosomes isolated from urines of RCC patient compared with control subjects. We enrolled 29 clear cell RCC patients and 23 control healthy subjects (CTRL), age and sex-matched, for urine collection and vesicle isolation by differential centrifugation. Such vesicles were morphologically and biochemically characterized and proved to share exosome properties. Proteomic analysis, performed on 9 urinary exosome (UE) pooled samples by gel based digestion followed by LC-MS/MS, led to the identification of 261 proteins from CTRL subject UE and 186 from RCC patient UE, and demonstrated that most of the identified proteins are membrane associated or cytoplasmic. Moreover, about a half of identified proteins are not shared between RCC and control UE. Starting from these observations, and from the literature, we selected a panel of 10 proteins, whose UE differential content was subjected to immunoblotting validation. Results show for the first time that RCC UE protein content is substantially and reproducibly different from control UE, and that these differences may provide clues for new RCC biomarker discovery.

1 February 2012 in Electrophoresis
Verified
Journal Article
Closed access
PDF file
PIERO DEL BOCCIOPIERO DEL BOCCIO
PIERO DEL BOCCIO
FRFrancesca Raimondo
Francesca Raimondo
Damiana PieragostinoDamiana Pieragostino
Damiana Pieragostino
LMLavinia Morosi
Lavinia Morosi
GCGabriele Cozzi
Gabriele Cozzi
AUAndrea Urbani
Andrea Urbani

2 December 2014 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
LALuca Ansaloni
Luca Ansaloni
ACand Federico Coccolini
and Federico Coccolini
LML Morosi
L Morosi
ABA Ballerini
A Ballerini
MCMarco Ceresoli
Marco Ceresoli
MZMassimo Zucchetti
Massimo Zucchetti
Hyperthermic intraperitoneal chemotherapy (HIPEC) is advised as a treatment option for epithelial ovarian cancer (EOC) with peritoneal carcinomatosis. This study was designed to define the pharmacokinetics of cisplatin (CDDP) and paclitaxel (PTX) administered together during HIPEC. Thirteen women with EOC underwent cytoreductive surgery (CRS) and HIPEC, with CDDP and PTX. Blood, peritoneal perfusate and tissue samples were harvested to determine drug exposure by high-performance liquid chromatography and matrix-assisted laser desorption ionization imaging mass spectrometry (IMS). The mean maximum concentrations of CDDP and PTX in perfusate were, respectively, 24.8±10.4 μg ml−1 and 69.8±14.3 μg ml−1; in plasma were 1.87±0.4 μg ml−1 and 0.055±0.009 μg ml−1. The mean concentrations of CDDP and PTX in peritoneum at the end of HIPEC were 23.3±8.0 μg g−1 and 30.1±18.3 μg−1g−1, respectively. The penetration of PTX into the peritoneal wall, determined by IMS, was about 0.5 mm. Grade 3–4 surgical complications were recorded in four patients, five patients presented grade 3 and two patients presented grade 4 hematological complications. HIPEC with CDDP and PTX after CRS is feasible with acceptable morbidity and has a favorable pharmacokinetic profile: high drug concentrations are achieved in peritoneal tissue with low systemic exposure. Larger studies are needed to demonstrate its efficacy in patients with microscopic postsurgical residual tumours in the peritoneal cavity.

11 October 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
PMPaola Marmiroli
Paola Marmiroli
BRBeatrice Riva
Beatrice Riva
EPEleonora Pozzi
Eleonora Pozzi
EBElisa Ballarini
Elisa Ballarini
DLDmitry Lim
Dmitry Lim
Valentina CarozziValentina Carozzi
Valentina Carozzi
Peripheral neurotoxicity is one of the most distressing side effects of oxaliplatin therapy for cancer. Indeed, most patients that received oxaliplatin experience acute and/or chronic severe sensory peripheral neuropathy. However, despite similar co-morbidities, cancer stage, demographics and treatment schedule, patients develop oxaliplatin-induced peripheral neurotoxicity with remarkably different severity. This suggests individual genetic variability, which might be used to glean the mechanistic insights into oxaliplatin neurotoxicity. We characterized the susceptibility of different mice strains to oxaliplatin neurotoxicity investigating the phenotypic features of neuropathy and gene expression profiles in dorsal root ganglia of six genetically different mice strains (Balb-c, C57BL6, DBA/2J, AJ, FVB and CD1) exposed to the same oxaliplatin schedule. Differential gene expression in dorsal root ganglia from each mice strain were assayed using a genome-wide expression analysis and selected genes were validated by RT-PCR analysis. The demonstration of consistent differences in the phenotypic response to oxaliplatin across different strains is interesting to allow the selection of the appropriate strain based on the pre-defined read-out parameters. Further investigation of the correlation between gene expression changes and oxaliplatin-induced neurotoxicity phenotype in each strain will be useful to deeper investigate the molecular mechanisms of oxaliplatin neurotoxicity.

14 May 2014 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
INI Fuso Nerini
I Fuso Nerini
LML Morosi
L Morosi
MZMassimo Zucchetti
Massimo Zucchetti
ABA Ballerini
A Ballerini
RGRaffaella Giavazzi
Raffaella Giavazzi
MDM D’iNcalci
M D’iNcalci